The Latest Cardiac and Vascular News
Malmö, Sweden, October 27, 2021 Acarix granted US CPT reimbursement code for CADScor System The editorial panel of the American Medical Association (AMA) today approved the Category III CPT® (CPT III) code application for the Acarix CADScor System®. The application was actively endorsed by the American College of Cardiology (ACC) and accepted by AMA without […]
Acarix announced today that the company has appointed Ms. Helen Ljungdahl Round as head of the company’s newly established US subsidiary Acarix Inc. Helen will assume her position in September 2021 and build the US organization. She will be a member of Acarix AB’s Executive Management Group. Acarix is a leader in AI driven diagnostics […]
A peer-reviewed publication in the September 2021 edition of PharmacoEconomics shows an estimated 12.3£ million savings to the English health care system per 100,000 eligible patients when using the Acarix CADScor system to rule out coronary artery disease (CAD). Coronary artery disease (CAD) is the most common heart and circulatory disease and is the leading […]
Malmö, Sweden, August 23, 2021 Preliminary Dan-NICAD II results to be presented at ESC Acarix AB (publ) today announced that the preliminary results of the Dan-NICAD II study will be presented at the ESC congress on 27AUG2021. The Dan-NICAD II trial was initiated in January 2018 to assess non-invasive methods in patients referred to CCTA (Coronary Computed Tomography Angiography) due to symptoms suggestive of […]
Press release Malmö, Sweden, January 13, 2021 Positive preliminary data from Acarix’s exploratory heart failure study SEISMO Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor®System on a potential heart failure application. The SEISMO trial was initiated in June 2018 to evaluate the possibility of developing an […]
Press release Malmö, Sweden December 9, 2020 Acarix announces the last patient included in Dan-NICAD II study After the inclusion of 1726 patients, Acarix announces that the last patient has been included in Dan-NICAD II, a study of non-invasive diagnostic testing in patients with suspected Coronary Artery Disease (CAD). The Dan-NICAD II, including 1726 patients […]
Press release (MAR) Malmö, Sweden, November 26, 2020 FDA identifies exclusive code for the CADScor® After yesterday’s announcement and further analysis of the FDA approval, Acarix AB today announce that the company’s marketing approval of the CADScor®System in the US was granted under a new generic type of code and device segment by the US […]
Press release (MAR) Malmö, Sweden November 25, 2020 Acarix receives US market approval for the CADScor® System Acarix AB (publ) today announced that the US Food and Drug Administration (FDA) has approved the company’s De Novo application for marketing approval of the CADScor®System in the US. “This is a major achievement and a significant recognition of […]
Press release Malmö, Sweden September 11, 2020 Acarix announce final outcome in oversubscribed rights issue Acarix AB (“Acarix” or the “Company”) has completed the new share issue of a maximum of 86,156,738 shares with preferential rights for the Company’s existing shareholders, which was resolved by the extra general meeting on 11 August 2020 (the “Rights […]
Press release Malmö, Sweden September 3, 2020 Acarix publishes a supplement to the prospectus The board of directors of Acarix AB (“Acarix” or the “Company”) has prepared a supplement to the prospectus regarding invitation to acquire shares in the approved preferential rights issue in Acarix which was approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) […]
